{"id":"NCT03877926","sponsor":"Emergent BioSolutions","briefTitle":"VELOCITY: An Anthrax Vaccine Clinical Study","officialTitle":"A Phase 3, Randomized, Double-blind, Parallel-group Trial to Evaluate the Lot Consistency, Immunogenicity, and Safety of AV7909 for Postexposure Prophylaxis of Anthrax in Healthy Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-11","primaryCompletion":"2020-08-06","completion":"2020-08-06","firstPosted":"2019-03-18","resultsPosted":"2021-12-21","lastUpdate":"2024-03-18"},"enrollment":3862,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Anthrax"],"interventions":[{"type":"BIOLOGICAL","name":"AV7909","otherNames":[]},{"type":"BIOLOGICAL","name":"BioThrax","otherNames":[]}],"arms":[{"label":"AV7909 Lot 1","type":"EXPERIMENTAL"},{"label":"AV7909 Lot 2","type":"EXPERIMENTAL"},{"label":"AV7909 Lot 3","type":"EXPERIMENTAL"},{"label":"BioThrax","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to evaluate the lot consistency (using three consecutively manufactured lots), safety, and ability of the AV7909 anthrax vaccine to generate an immune response in healthy adults and compare the response to that induced by the currently licensed vaccine, BioThraxÂ®, (Anthrax Vaccine Adsorbed; AVA) for post-exposure of anthrax disease.","primaryOutcome":{"measure":"Geometric Mean Titer (GMT) of Toxin Neutralizing Antibody (TNA) 50% Neutralization Factor (NF50) at Day 64","timeFrame":"Day 64 (seven weeks after second AV7909 vaccination)","effectByArm":[{"arm":"AV7909 Lot 1","deltaMin":0.753,"sd":null},{"arm":"AV7909 Lot 2","deltaMin":0.746,"sd":null},{"arm":"AV7909 Lot 3","deltaMin":0.718,"sd":null},{"arm":"BioThrax","deltaMin":0.335,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":35,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":1100},"commonTop":["Injection site pain","Upper respiratory tract infection","Vaccination complication","Procedural headache","Injection site induration"]}}